BAJAJ BROKING

Notification
No new Notification messages
Wagons Learning IPO is Open!
Apply for the Wagons Learning IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

1633

524494

IPCALAB

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

IPCA LABORATORIES LTD performance

Today’s low

Today’s high

₹ 1385.10 ₹ 1428.80
₹ 1401.20

52 week low

52 week high

₹ 1052.00 ₹ 1755.90
₹ 1401.20

Open Price

₹ 1401.50

Prev. Close

₹ 1392.40

Volume (Shares)

474031.00

Total traded value

₹ 6642.12

Upper Circuit

₹ 1670.80

Lower Circuit

₹ 1114.00

info

IPCA LABORATORIES LTD Share Price Update

As of the latest trading session, IPCA LABORATORIES LTD share price is currently at ₹ 1385.1, which is down by ₹ -7.30 from its previous closing. Today, the stock has fluctuated between ₹ 1385.10 and ₹ 1428.80. Over the past year, IPCA LABORATORIES LTD has achieved a return of 4.60 %. In the last month alone, the return has been 0.74 %. Read More...

IPCA LABORATORIES LTD fundamentals


  • Market cap (Cr)

    35,140.57

  • P/E Ratio (TTM)

    45.39

  • Beta

    0.73

  • Book Value / share

    265.60

  • Return on equity

    9.81%

  • EPS (TTM)

    32.66

  • Dividend yield

    0.29%

  • Net profit/quarter (Cr)

    267.56

info icon alternate text
  • Market cap (Cr)

    35,363.83

  • P/E Ratio (TTM)

    45.39

  • Beta

    0.66

  • Book Value / share

    265.60

  • Return on equity

    9.81%

  • EPS (TTM)

    32.66

  • Dividend yield

    0.29%

  • Net profit/quarter (Cr)

    267.56

info icon alternate text

IPCA LABORATORIES LTD Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 1662.68
Operating Expense 1324.57
Net Profit 267.56
Net Profit Margin (%) 16.09
Earnings Per Share (EPS) 10.55
EBITDA 428.50
Effective Tax Rate (%) 24.74
Particulars SEP 2024 (Values in Cr)
Revenue 1810.94
Operating Expense 1488.73
Net Profit 244.12
Net Profit Margin (%) 13.48
Earnings Per Share (EPS) 9.62
EBITDA 419.10
Effective Tax Rate (%) 28.03
Particulars JUN 2024 (Values in Cr)
Revenue 1565.86
Operating Expense 1293.36
Net Profit 204.13
Net Profit Margin (%) 13.03
Earnings Per Share (EPS) 8.05
EBITDA 368.63
Effective Tax Rate (%) 29.09
Particulars MAR 2024 (Values in Cr)
Revenue 1510.62
Operating Expense 1304.10
Net Profit 64.76
Net Profit Margin (%) 4.28
Earnings Per Share (EPS) 2.55
EBITDA 213.11
Effective Tax Rate (%) 49.12
Particulars DEC 2023 (Values in Cr)
Revenue 1506.82
Operating Expense 1324.01
Net Profit 136.94
Net Profit Margin (%) 9.08
Earnings Per Share (EPS) 5.40
EBITDA 290.38
Effective Tax Rate (%) 31.58
Particulars MAR 2024 (Values in Cr)
Revenue 6166.46
Operating Expense 5322.23
Net Profit 530.41
Net Profit Margin (%) 8.60
Earnings Per Share (EPS) 20.91
EBITDA 1189.31
Effective Tax Rate (%) 35.48
Particulars MAR 2023 (Values in Cr)
Revenue 5814.62
Operating Expense 5175.32
Net Profit 505.70
Net Profit Margin (%) 8.69
Earnings Per Share (EPS) 19.93
EBITDA 1023.04
Effective Tax Rate (%) 32.61
Particulars MAR 2022 (Values in Cr)
Revenue 5438.30
Operating Expense 4417.11
Net Profit 860.37
Net Profit Margin (%) 15.82
Earnings Per Share (EPS) 33.91
EBITDA 1291.00
Effective Tax Rate (%) 19.89
Particulars MAR 2021 (Values in Cr)
Revenue 5139.16
Operating Expense 3821.44
Net Profit 1140.77
Net Profit Margin (%) 22.19
Earnings Per Share (EPS) 90.08
EBITDA 1575.82
Effective Tax Rate (%) 17.33
Particulars MAR 2020 (Values in Cr)
Revenue 4367.43
Operating Expense 3647.15
Net Profit 652.46
Net Profit Margin (%) 14.93
Earnings Per Share (EPS) 51.64
EBITDA 979.45
Effective Tax Rate (%) 16.88
Particulars MAR 2024 (Values in Cr)
Book Value / Share 249.59
ROE % 8.69
ROCE % 12.92
Total Debt to Total Equity 0.24
EBITDA Margin 17.40
Particulars MAR 2023 (Values in Cr)
Book Value / Share 230.27
ROE % 8.70
ROCE % 11.59
Total Debt to Total Equity 0.20
EBITDA Margin 16.90
Particulars MAR 2022 (Values in Cr)
Book Value / Share 215.41
ROE % 17.92
ROCE % 20.26
Total Debt to Total Equity 0.11
EBITDA Margin 23.66
Particulars MAR 2021 (Values in Cr)
Book Value / Share 370.65
ROE % 27.59
ROCE % 30.56
Total Debt to Total Equity 0.09
EBITDA Margin 29.71
Particulars MAR 2020 (Values in Cr)
Book Value / Share 286.15
ROE % 17.88
ROCE % 19.51
Total Debt to Total Equity 0.14
EBITDA Margin 20.85
Particulars MAR 2024 (Values in Cr)
Book Value / Share 250.24
ROE % 9.81
ROCE % 14.12
Total Debt to Total Equity 0.21
EBITDA Margin 21.08
Particulars MAR 2023 (Values in Cr)
Book Value / Share 231.66
ROE % 8.91
ROCE % 11.67
Total Debt to Total Equity 0.20
EBITDA Margin 17.64
Particulars MAR 2022 (Values in Cr)
Book Value / Share 215.84
ROE % 16.82
ROCE % 19.15
Total Debt to Total Equity 0.10
EBITDA Margin 23.80
Particulars MAR 2021 (Values in Cr)
Book Value / Share 374.67
ROE % 27.06
ROCE % 30.20
Total Debt to Total Equity 0.08
EBITDA Margin 30.72
Particulars MAR 2020 (Values in Cr)
Book Value / Share 290.11
ROE % 19.15
ROCE % 20.63
Total Debt to Total Equity 0.13
EBITDA Margin 22.50
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 296.84
Total Assets 11101.28
Total Liabilities 11101.28
Total Equity 7727.00
Share Outstanding 253704218
Price to Book Ratio 4.95
Return on Assets (%) 4.93
Return on Capital (%) 6.01
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 1853.24
Total Assets 8626.43
Total Liabilities 8626.43
Total Equity 5915.32
Share Outstanding 253704218
Price to Book Ratio 3.50
Return on Assets (%) 5.46
Return on Capital (%) 6.39
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 640.66
Total Assets 7623.53
Total Liabilities 7623.53
Total Equity 5541.76
Share Outstanding 253704218
Price to Book Ratio 4.92
Return on Assets (%) 11.59
Return on Capital (%) 13.96
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 365.07
Total Assets 6068.36
Total Liabilities 6068.36
Total Equity 4716.18
Share Outstanding 126852109
Price to Book Ratio 5.08
Return on Assets (%) 18.78
Return on Capital (%) 22.94
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 180.92
Total Assets 5259.83
Total Liabilities 5259.83
Total Equity 3641.11
Share Outstanding 126352109
Price to Book Ratio 4.78
Return on Assets (%) 11.52
Return on Capital (%) 14.95
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 112.92
Total Assets 8659.27
Total Liabilities 8659.27
Total Equity 6348.71
Share Outstanding 253704218
Price to Book Ratio 4.95
Return on Assets (%) 6.12
Return on Capital (%) 7.09
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 1706.06
Total Assets 8446.97
Total Liabilities 8446.97
Total Equity 5877.30
Share Outstanding 253704218
Price to Book Ratio 3.50
Return on Assets (%) 5.98
Return on Capital (%) 6.93
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 595.50
Total Assets 7438.44
Total Liabilities 7438.44
Total Equity 5475.76
Share Outstanding 253704218
Price to Book Ratio 4.92
Return on Assets (%) 11.56
Return on Capital (%) 13.8
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 306.92
Total Assets 6010.13
Total Liabilities 6010.13
Total Equity 4752.72
Share Outstanding 126852109
Price to Book Ratio 5.08
Return on Assets (%) 18.98
Return on Capital (%) 22.93
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 152.40
Total Assets 5184.57
Total Liabilities 5184.57
Total Equity 3677.54
Share Outstanding 126352109
Price to Book Ratio 4.78
Return on Assets (%) 12.58
Return on Capital (%) 16.05
Particulars MAR 2024 (Values in Cr)
Net Income 842.67
Cash from Operations 1240.95
Cash from Investing -1291.79
Cash from Financing -552.55
Net change in Cash -899.69
Free Cash Flow 1651.55
Particulars MAR 2023 (Values in Cr)
Net Income 745.29
Cash from Operations 1029.46
Cash from Investing -725.00
Cash from Financing 507.24
Net change in Cash 588.05
Free Cash Flow 1523.93
Particulars MAR 2022 (Values in Cr)
Net Income 1135.72
Cash from Operations 1058.11
Cash from Investing -855.05
Cash from Financing 426.78
Net change in Cash 427.80
Free Cash Flow 1537.06
Particulars MAR 2021 (Values in Cr)
Net Income 1388.98
Cash from Operations 1335.72
Cash from Investing -520.69
Cash from Financing -305.82
Net change in Cash 263.62
Free Cash Flow 1697.27
Particulars MAR 2020 (Values in Cr)
Net Income 738.89
Cash from Operations 722.57
Cash from Investing -509.65
Cash from Financing -136.54
Net change in Cash -75.84
Free Cash Flow 1028.85
Particulars MAR 2024 (Values in Cr)
Net Income 822.16
Cash from Operations 1107.46
Cash from Investing -1355.18
Cash from Financing -464.88
Net change in Cash -989.55
Free Cash Flow 1467.68
Particulars MAR 2023 (Values in Cr)
Net Income 750.49
Cash from Operations 977.54
Cash from Investing -709.61
Cash from Financing 506.38
Net change in Cash 559.06
Free Cash Flow 1414.40
Particulars MAR 2022 (Values in Cr)
Net Income 1074.11
Cash from Operations 1023.88
Cash from Investing -814.00
Cash from Financing 426.04
Net change in Cash 443.76
Free Cash Flow 1475.51
Particulars MAR 2021 (Values in Cr)
Net Income 1379.96
Cash from Operations 1337.93
Cash from Investing -559.56
Cash from Financing -307.38
Net change in Cash 229.12
Free Cash Flow 1687.58
Particulars MAR 2020 (Values in Cr)
Net Income 784.97
Cash from Operations 707.84
Cash from Investing -499.13
Cash from Financing -138.67
Net change in Cash -76.37
Free Cash Flow 980.91
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 19.60 1.99 279.41 34.11 / 77.70
BLISS GVS PHARMA LTD 119.00 15.60 1.24 1253.91 92.25 / 184.95
CIPLA LTD 1549.65 25.08 4.41 125155.99 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 260.70 21.60 2.64 767.27 145.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 21.96 6.19 279.41 34.11 / 77.70
AMRUTAJAN HEALTH LTD 692.80 40.61 6.72 2002.93 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8665.50 129.24 31.88 21663.75 5000.00 / 9199.00
BLISS GVS PHARMA LTD 119.00 15.45 1.22 1253.91 92.25 / 184.95

IPCA LABORATORIES LTD Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
1401.20 0.63 redarrow
red-green-graph indicator
14 Bearish
2 Bullish
  • 5 Days 1409.60
  • 26 Days 1405.90
  • 10 Days 1410.60
  • 50 Days 1418.30
  • 12 Days 1409.70
  • 100 Days 1443.30
  • 20 Days 1406.40
  • 200 Days 1416.90
1398.30 PIVOT

First Support

1373.10

First Resistance

1417.60

Second Support

1353.80

Second Resistance

1442.80

Third Support

1328.60

Third Resistance

1462.10

RSI

49.38

ADX

7.16

MACD

3.75

Williams % R

-37.25

Commodity Channel Index (CCI)

6.82

Date

2025-04-30

Week

174693.00

Same Day

309698.00

Month

165321.00

1 Year

0.73

3 Year

0.56

Over 1 Month

0.74%

down

Over 1 Year

4.60%

down

Over 3 Months

-3.68%

down

Over 3 Years

11.51%

down

Over 6 Months

-10.30%

down

Over 5 Years

11.60%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

IPCA LABORATORIES LTD shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
8.45%
Promoter Holdings
44.72%
FII
10.75%
DII
36.06%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Kaygee Investments Private Limited 5.447839E7 (21.47%) Shareholding of Promoter and Promoter Group
Hdfc Mutual Fund - Hdfc Mid-cap Opportunities Fund 2.148117E7 (8.47%) Public Shareholding
Kaygee Laboratories Private Limited 1.677E7 (6.61%) Shareholding of Promoter and Promoter Group
Dsp Midcap Fund 1.5708204E7 (6.19%) Public Shareholding
Kotak Emerging Equity Scheme 1.4688543E7 (5.79%) Public Shareholding
Chandurkar Investments Private Limited 1.395601E7 (5.5%) Shareholding of Promoter and Promoter Group
Paschim Chemicals Pvt Ltd 1.0173E7 (4.01%) Shareholding of Promoter and Promoter Group
Sbi Life Insurance Co. Ltd 7226128.0 (2.85%) Public Shareholding
Premchand Godha 5814680.0 (2.29%) Shareholding of Promoter and Promoter Group
Nippon Life India Trustee Ltd-a/c Nippon India Growth Fund 5705808.0 (2.25%) Public Shareholding
Hdfc Life Insurance Company Limited 4899684.0 (1.93%) Public Shareholding
Usha M Chandurkar 4302000.0 (1.7%) Shareholding of Promoter and Promoter Group
Kotak Funds - India Midcap Fund 3274433.0 (1.29%) Public Shareholding
Usha Premchand Godha 2418740.0 (0.95%) Shareholding of Promoter and Promoter Group
Sameer M Chandurkar 2000000.0 (0.79%) Shareholding of Promoter and Promoter Group
Pranay Godha 1700990.0 (0.67%) Shareholding of Promoter and Promoter Group
Prashant Godha 1568644.0 (0.62%) Shareholding of Promoter and Promoter Group
Kalpana Jain 230000.0 (0.09%) Shareholding of Promoter and Promoter Group
Mexin Medicaments Private Limited 14058.0 (0.01%) Shareholding of Promoter and Promoter Group
Xbees Traders Llp 31000.0 (0.01%) Shareholding of Promoter and Promoter Group
Makers Laboratories Limited 960.0 (0.0%) Shareholding of Promoter and Promoter Group
Nirmal Jain 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Neetu Godha 4000.0 (0.0%) Shareholding of Promoter and Promoter Group
Bhawna Godha 5000.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

IPCA LABORATORIES LTD corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
22 Nov 2023 2.0 Interim 22 Nov 2023 Equity shares
22 Nov 2022 4.0 Interim 23 Nov 2022 Equity shares
22 Nov 2021 8.0 Interim 23 Nov 2021 Equity shares
13 Nov 2020 8.0 Interim 17 Nov 2020 Equity shares
18 Feb 2020 5.0 Interim 20 Feb 2020 Equity shares
06 Aug 2019 3.0 Final 08 Aug 2019 Equity shares
02 Aug 2018 1.0 Final 04 Aug 2018 Equity shares
27 Jul 2017 1.0 Final 29 Jul 2017 Equity shares
22 Jul 2015 1.0 Final 24 Jul 2015 Equity shares
18 Jul 2014 2.5 Final 22 Jul 2014 Equity shares
31 Oct 2013 2.5 Interim 01 Nov 2013 Equity shares
19 Jul 2013 2.0 Final 23 Jul 2013 Equity shares
01 Nov 2012 2.0 Interim 02 Nov 2012 Equity shares
20 Jul 2012 1.2 Final 24 Jul 2012 Equity shares
07 Feb 2012 1.0 Interim 2 08 Feb 2012 Equity shares
03 Nov 2011 1.0 Interim 07 Nov 2011 Equity shares
18 Jul 2011 1.2 Final 20 Jul 2011 Equity shares
01 Feb 2011 1.0 Interim 2 02 Feb 2011 Equity shares
28 Oct 2010 1.0 Interim 29 Oct 2010 Equity shares
16 Jul 2010 1.0 Final 20 Jul 2010 Equity shares
27 Jan 2010 4.0 Interim 2 28 Jan 2010 Equity shares
30 Oct 2009 5.0 Interim 03 Nov 2009 Equity shares
20 Jul 2009 4.0 Final 22 Jul 2009 Equity shares
27 Jan 2009 3.0 Interim 2 28 Jan 2009 Equity shares
07 Nov 2008 4.0 Interim 10 Nov 2008 Equity shares
14 Jul 2008 4.5 Final 16 Jul 2008 Equity shares
06 Nov 2007 3.5 Interim 07 Nov 2007 Equity shares
10 Jul 2007 4.0 Final 12 Jul 2007 Equity shares
02 Nov 2006 3.5 Interim 01 Jan 0001 Equity shares
09 Nov 2005 0.0 Interim 10 Nov 2005 Equity shares
13 Sep 2005 0.0 Final 15 Sep 2005 Equity shares
Ex-Date Ex-Bonus Ratio
31 Jan 2005 28 Jan 2005 1:1
Ex-Date Old FV NEW FV Record Date
10 Jan 2022 2.0 1.0 11 Jan 2022
22 Mar 2010 10.0 2.0 23 Mar 2010
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
22 Nov 2023 2.0 Interim 22 Nov 2023 Equity shares
22 Nov 2022 4.0 Interim 23 Nov 2022 Equity shares
22 Nov 2021 8.0 Interim 23 Nov 2021 Equity shares
13 Nov 2020 8.0 Interim 17 Nov 2020 Equity shares
18 Feb 2020 5.0 Interim 20 Feb 2020 Equity shares
06 Aug 2019 3.0 Final 08 Aug 2019 Equity shares
02 Aug 2018 1.0 Final 04 Aug 2018 Equity shares
27 Jul 2017 1.0 Final 29 Jul 2017 Equity shares
22 Jul 2015 1.0 Final 24 Jul 2015 Equity shares
18 Jul 2014 2.5 Final 22 Jul 2014 Equity shares
31 Oct 2013 2.5 Interim 01 Nov 2013 Equity shares
19 Jul 2013 2.0 Final 23 Jul 2013 Equity shares
01 Nov 2012 2.0 Interim 02 Nov 2012 Equity shares
20 Jul 2012 1.2 Final 24 Jul 2012 Equity shares
07 Feb 2012 1.0 Interim 2 08 Feb 2012 Equity shares
03 Nov 2011 1.0 Interim 07 Nov 2011 Equity shares
18 Jul 2011 1.2 Final 20 Jul 2011 Equity shares
01 Feb 2011 1.0 Interim 2 02 Feb 2011 Equity shares
28 Oct 2010 1.0 Interim 29 Oct 2010 Equity shares
16 Jul 2010 1.0 Final 20 Jul 2010 Equity shares
27 Jan 2010 4.0 Interim 2 28 Jan 2010 Equity shares
30 Oct 2009 5.0 Interim 03 Nov 2009 Equity shares
20 Jul 2009 4.0 Final 22 Jul 2009 Equity shares
27 Jan 2009 3.0 Interim 2 28 Jan 2009 Equity shares
07 Nov 2008 4.0 Interim 10 Nov 2008 Equity shares
14 Jul 2008 4.5 Final 16 Jul 2008 Equity shares
06 Nov 2007 3.5 Interim 07 Nov 2007 Equity shares
10 Jul 2007 4.0 Final 12 Jul 2007 Equity shares
02 Nov 2006 3.5 Interim 01 Jan 0001 Equity shares
09 Nov 2005 0.0 Interim 10 Nov 2005 Equity shares
13 Sep 2005 0.0 Final 15 Sep 2005 Equity shares
Ex-Date Ex-Bonus Ratio
31 Jan 2005 28 Jan 2005 1:1
Ex-Date Old FV NEW FV Record Date
10 Jan 2022 2.0 1.0 11 Jan 2022
22 Mar 2010 10.0 2.0 23 Mar 2010

IPCA LABORATORIES LTD Share Price

Ipca Laboratories Limited (IPCA) was incorporated on 19th October, 1949 under the name of 'The Indian Pharmaceutical Combine Association Limited.' Ipca is a fully integrated, pharmaceutical company manufacturing and marketing over 350 formulations and 80 API's covering various therapeutic segments. The products of the Company are now sold in over 100 countries across the globe. The Company has 18 manufacturing units in India manufacturing API's and formulations for the world market.

Ipca's APIs and Formulations produced at world class manufacturing facilities are approved by leading drug regulatory authorities including the US-Food and Drug Administration (FDA), UK-Medicines and Healthcare products Regulatory Agency (MHRA), South Africa-Medicines Control Council (MCC), Brazil-Brazilian National Health Vigilance Agency (ANVISA) and Australia-Therapeutic Goods Administration (TGA) with operations in over 100 countries.

Ipca is one of the biggest manufacturers in the world of APIs Atenolol (Antihypertensive), Chloroquine Phosphate (Antimalarial), Furosemide (Diuretic) and Pyrantel Salts (Anthelmintic) right from the basic stage. Ipca is also one of the largest suppliers of these APIs and their intermediates world over. The name of the company was changed to Ipca Laboratories Limited' in 6th August of the year 1964 and again name was changed to Ipca Laboratories Private Limited' in 13th January of the year 1966. Ipca had commissioned one of the first modern Pharma factory of yesteryears in the year 1969 at Mumbai. The present management took over the company in November of the year 1975. In the year 1976, started domestic marketing operations, the first company to offer sugarcoated Chloroquine tablets. Launched formulations of Metoclopramide under brand name 'Perinorm' for the first time in India during the year 1978. After two years, in 1980, the company had launched formulations of Bromhexine for the first time in India. Ipca's first APIs plant was commissioned at Ratlam in the year 1984 and also in the same period the second formulations plant was commissioned at Ratlam itself. Ipca's first APIs Plant for manufacturing of Chloroquine Phosphate was set up at Ratlam in the year 1986. As at 9th August 1988, again the company had changed its name to Ipca Laboratories Limited'. Ipca's status was converted to a Public Limited Company in 24th March of the year 1993 and also in the same year, the company had acquired Hoechst India's formulations unit at Kandla.

During the year 1994, Ipca had acquired API Plant from BDH Pharmaceuticals (a subsidiary of E. Merck) at Indore. In the year 1995, the modern formulations plant at Athal (Silvassa) came to line. After a year, in 1996, the company had commissioned new API R&D Centre at Mumbai. In 2000, received ISO 9001 certification for Athal Plant. The Company had incorporated two subsidiaries in Mauritius in the year of 2001 under the name of Solway Investments Ltd and 'Sundridge Management Ltd. during the year 2002, launched new domestic marketing division, Intima to promote established brands with a focus on micro-interior marketing and also in the same year incorporated wholly owned subsidiary in Brazil under the name of Laboratories Ipca Do Brasil Ltd. Launched new domestic marketing division in the year 2003 as Activa, dedicated to Rheumatology Care. Forbes, a leading US business magazine, selected among its top 200 successful, rising companies outside USA in the same year 2003. Commissioned new formulation plant at Silvassa in the year 2004. Forbes selected Ipca, for the second consecutive year as one among the first 200 'Best under a Billion Company' in Asia.

Innotech Pharma Limited was merged with Ipca in August of the year 2005. During the same year, Ipca entered in to Joint Venture with Holley Group of China for marketing Artemisinin based API and Formulation. Joint Venture setup in SAIF Zone, Sharjah, U.A.E. and named as ACTIVA Pharmaceuticals FZC. Also acquired Cardiac brand ISORDIL from Wyeth Limited. Ipca had entered into strategic alliance with Ranbaxy Pharmaceuticals Inc. for the U.S market in the year 2006. The Company's new plant at Dehradun was commenced operation from 5th May of the year 2006. As of January 2007, Ipca and Ranbaxy alliance had received U.S. FDA marketing approval for Atenolol Tablets. Ipca's New Biotech Research & Development Unit was inaugurated at Mumbai in March of the same year 2007. Ipca had awarded by Forbes Inc., as one of the 'Best under a Billion' Forbes Global's 200 Best Small Companies, 2007. Ipca had received final approval from the US FDA, for Metoclopramide tablets in June 2008. The Company had signed a partnership agreement with Clinton Foundation in July of the same year 2008.

The Company plans to develop various APIs/intermediates having good potential for exports and local market. It plans additional investment in manpower, latest instrumentation to upgrade and strengthen R&D facilities. Also, the company aims at developing newer drug delivery systems along with developing formulations for developed market and bio-equivalence studies of the same.

During the FY 2015, the Company acquired assets of formulations manufacturing unit situated at Plot No. T-139, MIDC,Tarapur, Palghar - 401506. The Company has also acquired as a going concern on slump sale basis the High Potency (Hormonal) Oral Solid Dosage formulations manufacturing unit situated at Sector III, Pithampur, Dhar (Madhya Pradesh) together with its employees. This manufacturing unit has the approval of WHO-GMP, INVIMA Colombia and German.

During the year 2015, the Company acquired joint management stake in M/s. Krebs Biochemicals & Industries Ltd., a listed public limited company with fermentation based APIs manufacturing facilities situated at Visakhapatnam and Nellore (Andhra Pradesh). The Company had also made public announcement of open offer to the public shareholders of the said company under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

M/s. Krebs Biochemicals and Industries Ltd. became an associate company. No other company has become / ceased to be subsidiary or joint venture or associate company during the financial year 2015.

During the year, as a part of group re-construction, Ipca Laboratories (UK) Ltd. acquired the entire issued share capital of Onyx Scientific Ltd., UK from its wholly owned subsidiary, Onyx Research Chemicals Ltd., U.K. on 25th March, 2015 in lieu of capital dividend declared by the said company. Consequent to this, Onyx Scientific Ltd., UK has become wholly owned subsidiary of Ipca Laboratories (UK) Ltd. from the said date. From the said date, Onyx Research Chemicals Ltd. UK has ceased to trade and is in the process of being dissolved. The wholly owned subsidiary company, Ipca Pharmaceuticals (Shanghai) Ltd., incorporated in the Peoples Republic of China, is in the process of being voluntarily closed down.

During the year 2016, the wholly owned subsidiary companies, Ipca Pharmaceuticals (Shanghai) Ltd. incorporated in the People's Republic of China and National Druggists Pty Ltd. incorporated in the Republic of South Africa were voluntarily closed down. Onyx Research Chemicals Limited, U.K. merged with its holding company Ipca Laboratories (UK) Ltd. Consequent to this, Onyx Scientific Ltd. has now become wholly owned subsidiary of Ipca Laboratories (U.K.) Ltd. which in turn is the wholly owned subsidiary of the Company.

During the year 2018, the Company acquired 100% share capital of Pisgah Labs Inc. a North Carolina Corporation, Old Hendersonville Highway, Pisgah Forest, North Carolina, USA through Ipca Pharmaceutical Inc., USA (Company's wholly owned subsidiary) and Onyx Scientific Ltd., U.K (Onyx) (Company's wholly owned step down subsidiary) for US$ 9.65 millions, free of debt. Pisgah was founded as a contract manufacturer and developer of active pharmaceutical ingredients (APIs) and intermediates.

During the year 2019-20, the Company acquired 100% paid-up share capital of M/s. Ramdev Chemical Private Limited on 24th April, 2019 and became its wholly owned subsidiary.

During the year 2021, M/s. Trophic Wellness Private Ltd., got incorporated with the Company and became its subsidiary.

During year 2022, Company acquired 26.57% of share capital of M/s. Lyka Labs Limited with the Promoters of the said Company. It made a Public Offer to acquire additional 26% Equity Shares of the said Company from its public shareholders, where the Company now holds 26.58% of the equity share capital of the said Company.

During the financial year 2022-23, the Company acquired further 6.53% of the paid-up equity share capital of Trophic Wellness Private Ltd. With this acquisition, the Company holds 58.88% of the paid-up equity share capital of the said Company.

During the financial year 2022-23, the Company acquired, thru preferential allotment, further 4.78% of the paid-up equity share capital of Lyka Labs Ltd. Also, in the month of April, 2023, the Company acquired another 4.98% of the paid-up share capital of the said company thru part conversion of warrants issued on preferential basis. With these share allotments, the Company now holds 36.34% of the paid-up equity share capital of Lyka Labs Ltd.

During 2022-23, the merger of M/s. Ramdev Chemical Pvt. Ltd. and M/s. Tonira Exports Ltd., Company's wholly owned subsidiaries with the Company was effective from 1st April, 2022.

The Company's Active Pharmaceuticals Ingredients (APIs) at Dewas (Madhya Pradesh) commenced trial production in September, 2022.

Parent organization Indian Private
NSE symbol IPCALAB
Founded 1949
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Ipca Laboratories Ltd?

Answer Field

The share price of Ipca Laboratories Ltd for NSE is ₹ 1385.1 and for BSE is ₹ 1393.9.

What is the Market Cap of Ipca Laboratories Ltd?

Answer Field

The market cap of Ipca Laboratories Ltd for NSE is ₹ 3,51,40.57 Cr. and for BSE is ₹ 3,53,63.83 Cr. as of now.

What is the 52 Week High and Low of Ipca Laboratories Ltd?

Answer Field

The 52 Week High and Low of Ipca Laboratories Ltd for NSE is ₹ 1755.90 and ₹ 1052.00 and for BSE is ₹ 1757.65 and ₹ 1060.95.

How to Buy Ipca Laboratories Ltd share?

Answer Field

You can trade in Ipca Laboratories Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Ipca Laboratories Ltd?

Answer Field

The 1 year returns on the stock has been 4.60%.

What is the Current Share Price of Ipca Laboratories Ltd?

Answer Field

Ipca Laboratories Ltd share price is for NSE ₹ 1385.1 & for BSE ₹ 1393.9 as on Apr 30 2025 03:29 PM.

What is the Market Cap of Ipca Laboratories Ltd Share?

Answer Field

The market cap of Ipca Laboratories Ltd for NSE ₹ 3,51,40.57 & for BSE ₹ 3,53,63.83 as on Apr 30 2025 03:29 PM.

What is the P/E Ratio of Ipca Laboratories Ltd Share?

Answer Field

As on Apr 30 2025 03:29 PM the price-to-earnings (PE) ratio for Ipca Laboratories Ltd share is 45.39.

What is the PB ratio of Ipca Laboratories Ltd Share?

Answer Field

As on Apr 30 2025 03:29 PM, the price-to-book (PB) ratio for Ipca Laboratories Ltd share is 265.60.

How to Buy Ipca Laboratories Ltd Share?

Answer Field

You can trade in Ipca Laboratories Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Ipca Laboratories Ltd Share on Bajaj Broking App?

Answer Field

To buy Ipca Laboratories Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Ipca Laboratories Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|